National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology, Ministry of Education, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital, Central South University, Changsha, China.
Department of Pathology, The Second Xiangya Hospital, Central South University, Changsha, China.
Front Immunol. 2022 Sep 15;13:970588. doi: 10.3389/fimmu.2022.970588. eCollection 2022.
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignant tumor of the digestive system. Its grim prognosis is mainly attributed to the lack of means for early diagnosis and poor response to treatments. Genomic instability is shown to be an important cancer feature and prognostic factor, and its pattern and extent may be associated with poor treatment outcomes in PDAC. Recently, it has been reported that long non-coding RNAs (lncRNAs) play a key role in maintaining genomic instability. However, the identification and clinical significance of genomic instability-related lncRNAs in PDAC have not been fully elucidated.
Genomic instability-derived lncRNA signature (GILncSig) was constructed based on the results of multiple regression analysis combined with genomic instability-associated lncRNAs and its predictive power was verified by the Kaplan-Meier method. And real-time quantitative polymerase chain reaction (qRT-PCR) was used for simple validation in human cancers and their adjacent non-cancerous tissues. In addition, the correlation between GILncSig and tumor microenvironment (TME) and epithelial-mesenchymal transition (EMT) was investigated by Pearson correlation analysis.
The computational framework identified 206 lncRNAs associated with genomic instability in PDAC and was subsequently used to construct a genome instability-derived five lncRNA-based gene signature. Afterwards, we successfully validated its prognostic capacity in The Cancer Genome Atlas (TCGA) cohort. In addition, careful examination of the transcriptome expression profile of PDAC patients, we discovered that GILncSig is associated with EMT and an adaptive immunity deficient immune profile within TME.
Our study established a genomic instability-associated lncRNAs-derived model (GILncSig) for prognosis prediction in patients with PDAC, and revealed the potential functional regulatory role of GILncSig.
胰腺导管腺癌(PDAC)是一种高度侵袭性的消化系统恶性肿瘤。其预后不良主要归因于早期诊断手段的缺乏和对治疗的反应不佳。基因组不稳定性被认为是癌症的一个重要特征和预后因素,其模式和程度可能与 PDAC 的治疗效果不佳有关。最近,有报道称长非编码 RNA(lncRNA)在维持基因组不稳定性方面发挥着关键作用。然而,PDAC 中与基因组不稳定性相关的 lncRNA 的鉴定及其临床意义尚未得到充分阐明。
基于多元回归分析结果,结合与基因组不稳定性相关的 lncRNA,构建了基因组不稳定性衍生的 lncRNA 特征(GILncSig),并通过 Kaplan-Meier 法验证了其预测能力。实时定量聚合酶链反应(qRT-PCR)用于在人类癌症及其相邻非癌组织中进行简单验证。此外,通过 Pearson 相关性分析研究了 GILncSig 与肿瘤微环境(TME)和上皮-间充质转化(EMT)的相关性。
计算框架确定了 206 个与 PDAC 中基因组不稳定性相关的 lncRNA,并随后用于构建基于五个基因组不稳定性衍生 lncRNA 的基因特征。之后,我们成功验证了其在癌症基因组图谱(TCGA)队列中的预后能力。此外,通过对 PDAC 患者的转录组表达谱进行仔细检查,我们发现 GILncSig 与 EMT 和 TME 中的适应性免疫缺陷免疫特征有关。
本研究建立了一个用于预测 PDAC 患者预后的基因组不稳定性相关 lncRNA 衍生模型(GILncSig),并揭示了 GILncSig 的潜在功能调节作用。